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Abstract: Clear evidence supports a role for circulating 
and locally-produced osteocalcin (OC) in the pathophysi-
ology of cardiovascular (CV) lesions and CV risk, also 
in combination with metabolic changes, including type 
2 diabetes mellitus (T2DM). Reduced plasma OC levels 
are associated with greater incidence of pathological CV 
changes, like arterial and valvular calcification, coro-
nary and carotid atherosclerosis and increased carotid 
intima-media thickness. The actual relationship between 
OC levels and incidence of major CV events is, however, 
still unclear. Moreover, reduced circulating OC levels have 
been mostly associated with insulin resistance, metabolic 
syndrome or T2DM, indicating relevant OC actions on pan-
creatic β-cells and insulin secretion and activity. Based on 
these observations, this review article will attempt to sum-
marize the current evidence on the potential usefulness of 
circulating OC as a biomarker for CV and metabolic risk, 
also evaluating the currently open issues in this area of 
research.
Keywords: atherosclerosis; cardiovascular risk; metabolic 
syndrome; osteocalcin; type 2 diabetes mellitus.
Introduction
Primary cardiovascular (CV) and metabolic prevention is 
nowadays a very relevant issue worldwide and the avail-
ability of novel and reliable predictive biomarkers, to 
be added and integrated with those already validated, 
is urgently required in order to better identify individu-
als at greater primary and secondary CV and metabolic 
risk. Indeed, a number of clinical trials, aimed at evalu-
ating drug effects on CV endpoints, suggested that a 
 relevant residual CV risk remains, in spite, for example, 
of low density lipoprotein-cholesterol (LDL-C) reduction 
well below specific cut-off values [1]. Identification and 
validation of circulating biomarkers, potentially useful 
in primary and secondary CV and metabolic risk assess-
ment is thus necessary. Recent observations have shown 
reciprocal functional interactions between organs, such 
as the adipose tissue and the endocrine pancreas, con-
trolling intermediary metabolism, and bone [2–4]. More 
specifically, adipose-borne leptin and adiponectin have 
been found to regulate bone turnover in a complex 
way, whereas osteocalcin (OC), a bone protein mainly 
expressed by osteoblasts, can promote insulin sensitiv-
ity and insulin secretion by pancreatic β-cells as well as 
their proliferation (Figure 1). In addition, measurement 
of plasma OC concentration has also been proposed as a 
potential biomarker of cardiometabolic risk, along with 
its established clinical significance as a biomarker of 
bone turnover [5]. Reduced plasma OC levels were indeed 
found to be associated with greater incidence of patho-
logical CV changes, like arterial and valvular calcification 
[6, 7], carotid atherosclerosis [8], and increased carotid 
intima-media thickness [9]. Moreover, reduced circulating 
OC levels have consistently been associated with the pres-
ence of insulin resistance, metabolic syndrome and type 2 
diabetes mellitus (T2DM) [10, 11], clearly linked to athero-
sclerosis development [8].
Despite this body of data, the actual relationship 
between OC levels and incidence of major CV events is 
still unclear, since some studies found no association 
of OC with stroke and myocardial infarction, at least in 
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specific ethnic cohorts [12], whereas others reported lower 
OC in younger subjects with premature myocardial infarc-
tion [13]. Based on these observations, the purpose of this 
review article is to summarize the current evidence on the 
potential usefulness of circulating OC as a biomarker for 
CV and metabolic risk. To this purpose, the PubMed and 
Embase databases were searched up to November 2015 for 
human studies addressing this topic.
Measurement of circulating 
 osteocalcin concentrations
OC is the most important noncollagen protein in bone 
matrix, accounting for approximately 1% of the total 
protein in human bone. OC, the product of the bone 
γ-carboxyglutamate protein (BGLAP) gene, is a bone-spe-
cific protein of 46–50 aminoacid residues, that undergoes 
post-translational modifications by vitamin K-dependent 
γ-carboxylation of three glutamic acid residues [10]. Its 
production is dependent upon vitamin K and is stimu-
lated by 1,25 dihydroxy vitamin D. Newly synthesized OC 
is partly incorporated into the bone matrix and partly 
released into the bloodstream. The extent of OC carboxy-
lation results in circulating OC isoforms with different 
biological activities, ranging from bone mineralization, 
mainly by carboxylated OC (cOC) to insulin sensitization, 
Osteocalcin
(uncarboxylated)
Vascular effects
Metabolic
effects
Figure 1: Osteocalcin is produced by bone osteoblasts and partly 
released into the bloodstream.
Circulating osteocalcin isoforms show a different extent of carboxy-
lation and consequently different biological activities, including 
the regulation of vascular calcification and atherosclerosis and the 
modulation of insulin secretion by pancreatic β cells and insulin 
resistance in the adipose and muscle tissues.
mainly due to uncarboxylated OC (ucOC) [14]. The clinical 
use of plasma/serum OC concentration measurement is 
mainly useful in monitoring and assessing the effective-
ness of antiresorptive therapy in patients treated for osteo-
penia, osteoporosis, Paget’s disease, or other disorders in 
which OC levels are elevated. In addition, OC assay may 
be useful in the diagnosis of medical conditions associated 
with increased bone turnover, like bone cancer metasta-
ses, primary hyperparathyroidism and renal osteodystro-
phy. Immunochemical and chromatographic studies have 
demonstrated considerable heterogeneity for concentra-
tions and molecular forms of circulating OC in normal indi-
viduals and in patients with osteoporosis, chronic renal 
failure, and Paget’s disease. OC (1–49) and its fragments, 
including OC (1–43), are released into the blood stream. 
Serum OC (1–43) is also generated by the catabolic break-
down of OC (1–49) in the circulation, liver and kidney, as 
well as by degradation during storage of samples, because 
a labile six-amino acid C-terminal sequence, at room tem-
perature, is cleaved off. Therefore, the measurement of the 
more stable N-terminal and mid-regional OC [N-MID OC, 
corresponding to OC (1–43/49)] is clinically more useful 
[15]. Different immunometric assays for the measurement 
of plasma/serum OC as well as ucOC have been developed. 
They include manually performed methods, such as immu-
nometric approaches (ELISA, EIA), utilized in the past for 
clinical purposes. today mainly used in research studies 
and selectively able to detect the different OC molecular 
species, including ucOC. Nowadays, for clinical purposes, 
automated methods like 2-site immunometric (sandwich) 
assays using electrochemiluminescence (ECLIA) detection 
are preferred, since they are able to detect both the stable 
N-MID-fragment and intact OC and show a better precision 
and accuracy than manually performed assays [16]. OC 
reference values for adult subjects are around 8–42 ng/mL 
[17]. Elevated levels of OC generally indicate increased 
bone turnover. In patients taking antiresorptive agents, a 
decrease  ≥ 20% from baseline OC level after 3–6 months of 
therapy suggests effective response to treatment [18]. More-
over, patients with diseases such as hyperparathyroidism, 
which can be cured, should have a reduction of OC to the 
reference range within 3–6 months after complete cure. In 
the case of assays making use of biotin-streptavidin inter-
action, to avoid assay interference from biotin in patients 
receiving therapy with high doses of this vitamin, it is 
appropriate to wait at least 8 h after the last biotin admin-
istration before collecting a blood specimen. Specific 
cautions in the interpretation of OC values include the fol-
lowing aspects. As OC is cleared by the kidneys, elevations 
may be observed in patients with impaired renal function 
without increased bone turnover. As OC is regulated by 
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1,25 dihydroxy vitamin D and vitamin K, serum OC may not 
reflect bone formation in patients treated with the former 
or antagonists of the latter.
Osteocalcin and cardiovascular risk
Different but related vascular lesions, ranging from vascu-
lar calcification to atherosclerotic plaques, are associated 
to the development of arterial diseases, leading to hyper-
tension and ischemic organ damage, such as myocardial 
infarction and stroke. As a general statement, several, but 
not all, cross-sectional and longitudinal studies, mostly 
conducted in the Chinese and Korean populations, sug-
gested the existence of a link between lower circulating 
OC levels and atherosclerosis development and CV disease 
(Tables 1 and 2). Among the different vascular pathologi-
cal changes leading to CV disease, ectopic CV calcifica-
tion appears related to a complex alteration of mineral 
metabolism at arterial and valvular sites, due to imbal-
ance of circulating and local OC actions and CV miner-
alization, bearing similarities to osteogenesis in bone [44] 
and leading to reduced vessel elasticity and compliance. 
CV calcification has frequently been associated to genetic 
predisposition and aging [45] and, similarly to atheroscle-
rosis, it may also be the consequence of low-grade chronic 
inflammation and endothelial dysfunction, promoting 
the differentiation of smooth muscle cells, from the arte-
rial wall, to osteoblast-like cells [7]. Moreover, according 
to recent views, cells with an osteoblast-like phenotype 
may also derive from circulating stem cells [46]. These 
osteoblast-like subpopulations are able to form miner-
alized nodules and to express OC and other molecules 
able to promote calcification [7]. This latter process is 
thus the final consequence of an imbalance between 
pro-calcification agents and a series of inhibitors of arte-
rial calcification, which include fetuin-A and adiponec-
tin [45]. Relevant to this pathophysiological process, a 
recent cross-sectional study on 162 subjects reported that 
higher concentrations of serum ucOC and higher ucOC:OC 
ratio are associated to coronary artery calcification in 
men, independent of conventional CV risk factors [21]. 
Moreover, in a prospective cohort of 774 men followed for 
10 years, higher baseline OC concentrations were associ-
ated with lower progression rate of abdominal aortic calci-
fication and lower mortality [41], suggesting that OC level 
might be an independent indicator of CV risk. Moreover, 
in T2DM men, but not women, OC and ucOC levels were 
negatively associated with abdominal aortic calcification 
score [22].
Locally-produced OC may also play a relevant patho-
genetic role also for atherosclerotic disease, although 
this cannot obviously be taken into consideration when 
measuring this marker in the peripheral circulation. 
Indeed, in addition to bone osteoblasts and the above-
mentioned osteoblast-like cells in the vascular wall, other 
possible cellular sources of OC with potential CV impact 
appear to be also present in the circulation. Endothelial 
progenitor cells expressing OC are strongly associated 
with early and unstable coronary artery disease [47] and 
to severe calcific stenosis of the aortic valve [6]. In addi-
tion, platelets also express and release OC to a greater 
extent in patients with occlusive carotid artery disease, 
with a peculiar localization in atherosclerotic plaques, 
but not in normal tissue [48]. OC-expressing osteogenic 
monocytes in the coronary microcirculation are associ-
ated with specific features of patients with early coro-
nary atherosclerosis and accumulate in the border region 
of plaques [49]. Interestingly, osteoclast-like cells have 
also been identified in atherosclerotic lesions, especially 
in association to extracellular matrix destruction, local 
mineral resorption and aneurysmal disease, thus sug-
gesting a selective role in the pathogenesis of this latter 
vascular disease [7].
The relationship between lower circulating OC levels 
and atherosclerotic disease has been underlined by 
several clinical studies. A recent cross-sectional study 
conducted in 461 Chinese subjects showed an inverse rela-
tionship between OC levels, coronary artery disease and 
its severity, being OC lower in patients with diagnosed 
coronary heart disease (CHD), independently of metabolic 
markers [38]. The association of lower ucOC with coronary 
artery disease has also been observed in a case-control 
study conducted in Korean patients who underwent coro-
nary artery bypass graft surgery [39].
Circulating OC levels also seem to be an independent 
risk factor for carotid atherosclerosis (Table 1). A nega-
tive relationship between OC concentrations and carotid 
intima-media thickness and presence of atherosclerotic 
plaques has been reported in two Chinese cohorts, one 
including 1319 postmenopausal women with subclini-
cal atherosclerosis [9] and one with 1077 middle-age 
and elderly males, independent of altered glucose 
 metabolism [19].
Cross-sectional studies showed that lower serum OC 
levels are associated with greater CV risk and CV disease 
incidence as well as to relevant glucometabolic changes 
or metabolic syndrome in a large middle-age and elderly 
Chinese population with self-reported CV disease [26] 
and in Chinese men [40]. Moreover, a recent case-control 
study in 302 subjects reported that in a large cohort of 
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patients with acute myocardial infarction at a young age, 
a rare disease with poor prognosis, circulating OC levels 
were decreased at both acute and stable (after 1  year) 
phases of disease [13]. Despite this body of data, the 
actual relationship between OC levels and incidence of 
major CV events remains unclear (Table 2). The complex-
ity of such relationship is indeed underlined by studies 
indicating that not only reduced, but also elevated OC 
levels predict all-cause and CV disease-related mortality, 
thus following a U shaped relationship, with subjects at 
both ends of the distribution at increased risk, as shown 
for older men [42] and in a large cohort of men at high 
CV risk [43]. In a population-based longitudinal cohort 
study conducted in 1319 subjects, it was observed that 
higher OC was associated with reduced CV disease risk 
in older-old men and with increased CV disease risk in 
older-old women, emphasizing that gender differences 
may represent a further level of complexity in this issue 
[23]. Interestingly, it has been reported that not lower, 
but higher OC levels were associated with CHD, as well 
as with pathological intima-media thickness, carotid 
plaques and aortic calcifications in T2DM patients [24]. 
Conversely, no association of OC and CV disease occur-
rence has also been reported. Specifically, a large 8.7 year 
longitudinal (primarily retrospective) study in the Korean 
population reported that total OC was not associated with 
the development of CV disease, although OC values were 
inversely correlated with obesity and abnormal plasma 
glucose and lipids [12]. In addition, such relationship was 
also not found in 476 metabolically healthy Chinese sub-
jects of both genders [20].
Osteocalcin, glucose and lipid 
metabolism
Accumulating experimental and clinical evidence sug-
gests that serum OC levels are associated with favorable 
glycometabolic conditions, as elevated OC is associated 
with improved insulin secretion and sensitivity, as well 
as better glycemic control [50, 51]. Conversely, reduced 
OC levels have consistently been associated with the 
presence of insulin resistance, atherogenic dyslipidemia, 
metabolic syndrome or T2DM in different ethnic groups, 
as assessed in cross-sectional studies and meta-analises 
[10, 11, 26, 52] (Table 1). More specifically, in a large cross-
sectional study on a Chinese cohort, OC levels were nega-
tively correlated with fasting serum insulin, homeostasis 
model assessment of insulin resistance (HOMA-IR), tri-
glycerides and total cholesterol, and positively to homeo-
stasis model assessment of β-cell function. Moreover, in 
men, OC negatively correlated with body mass index, 
diastolic blood pressure, fasting plasma glucose and 2-h 
oral glucose tolerance test glucose after adjustment for 
age, whereas in post-menopausal women, OC correlated 
Table 2: Clinical studies evaluating osteocalcin and cardiovascular disease.
Authors, year   Design   n  Biomarkers  Assay  Main outcome   References
Osteocalcin and cardiovascular disease
 Hwang et al., 2015   Longitudinal   1290  Serum OC   EIA   No association of OC with incident CVD   [12]
 Goliasch et al., 2011   Case-control   302  Serum OC   ECLIA   Association of lower OC with premature 
myocardial infarction (young subjects)
  [13]
 Zhang et al., 2010   Cross-sectional  461  Serum OC   ECLIA   Association of lower OC with coronary 
heart disease
  [38]
 Kim et al., 2015   Case-control   61+61  OC, ucOC   ELISA   Association of lower ucOC with coronary 
heart disease
  [39]
 Bao et al., 2011   Cross-sectional  181  Serum OC   ECLIA   Association of lower OC with severity of 
coronary atherosclerosis/MetS
  [40]
Osteocalcin and cardiovascular disease-related mortality
 Confavreux et al., 2013  Prospective   774  Serum OC   IRMA   Association of high OC with lower 
abdominal aortic calcification/mortality
  [41]
 Yeap et al., 2012   Prospective   3542  Serum OC   ECLIA   U shaped association of OC with all-
cause/CVD-related mortality (older men)
  [42]
 Lerchbaum et al., 2013  Cross-sectional  2271  Serum OC   ECLIA   U shaped association of OC with fatal 
events in men at high CVD risk
  [43]
C-IMT, Carotid intima-media thickness; CVD, cardiovascular disease; ECLIA, electrochemiluminescence immunoassay; EIA, enzyme immu-
noassay; ELISA, enzyme-linked immunosorbent assay; HOMA-IR, homeostasis model assessment of insulin resistance; IRMA, immunora-
diometric assay; MetS, metabolic syndrome; OC, osteocalcin; RIA, radioimmunoassay; ucOC, uncarboxylated osteocalcin; T2DM, type 2 
diabetes mellitus.
Brought to you by | Università degli Studi di Milano
Authenticated
Download Date | 6/16/16 12:48 PM
6      Magni et al.: Oosteocalcin and cardiometabolic risk
negatively with waist-hip ratio, LDL-C and C-reactive 
protein, and positively with adiponectin, apparently 
an independent predictor of circulating OC levels [26]. 
Interestingly, OC levels maintain their association with 
improved glucose tolerance and insulin secretion and 
sensitivity, independent of plasma adiponectin level [27]. 
The negative correlation between abdominal obesity and 
serum OC was confirmed by other studies in different 
ethnic groups [28, 29].
As OC levels appear to be negatively related to age, it 
is interesting to report that the independent inverse cor-
relation between OC and CV risk parameters, including 
lipid profile, fasting plasma glucose and insulin, is atten-
uated or lost in healthy young adults, when adjusted for 
fat mass or lifestyle factors, such as physical activity [30]. 
In another study, OC levels were inversely associated with 
T2DM in Latino adults, but not in children [31], whereas, 
in obese children, OC was lower and related to insulin 
resistance and leptin in both cross-sectional and longitu-
dinal analyses [53]. Moreover, serum ucOC was found to 
be higher in children from families with metabolic syn-
drome and thus at potential CV risk [25]. In a cross-sec-
tional study in young adults, OC and cOC, but not ucOC, 
were found to be inversely associated with obesity, insulin 
resistance, and cardiovascular risk factors [23].
As with the incidence of CV events, it is not clear 
whether lower OC levels predict the development 
of T2DM in the long-term, since related reports are 
inconsistent. A prospective, nested case-control study 
showed that serum cOC and ucOC were lower in diabetic 
subjects, compared to controls, and were associated 
with an increased risk of incident T2DM [32]. In agree-
ment with most cross-sectional studies, conducted in 
subjects with impaired glucose tolerance or T2DM, in 
a large Korean male cohort, baseline lower serum total 
OC levels were associated with less favorable metabolic 
parameters [33]. However, a longitudinal evaluation 
of this population, over a more than 8 year follow-up, 
found that OC was not associated with the incidence of 
new T2DM, after adjustment for other risk factors [33]. 
This observation was also extended by the same authors 
to younger men and pre- and post-menopausal women. 
On the other hand, lower total OC was associated with 
T2DM development in a nested case-control study in 
men with a 10-year follow-up [34]. Taken together, these 
observations suggest that the association between OC 
levels and glucose tolerance in humans needs to be 
better clarified.
It is well established that the presence of impaired 
glucose tolerance or T2DM accelerates progression of ath-
erosclerotic lesions. Indeed, lower OC levels have been 
shown in Chinese patients with both metabolic syndrome 
and severe coronary disease [40]. Other studies also 
reported a negative correlation between OC levels and 
parameters of atherosclerosis in T2DM patients [8]. Inter-
estingly, in most studies, the association between lower 
OC and CV risk or damage is still present after adjustment 
for metabolic markers, suggesting that OC may affect CV 
risk through independent mechanisms. In this context, 
the study by Reyes-Garcia et  al. should be mentioned 
again, as a relationship between higher OC levels and 
CV lesions and prevalence of coronary heart disease was 
actually observed in T2DM patients [24].
A limitation of several clinical studies is that they 
evaluated only total OC levels. Thus, it interesting to 
report observation on the association of cOC and ucOC 
with CV and metabolic markers. Specifically, in middle-
aged male subjects, elevated levels of both cOC and 
ucOC were associated with improved glucose tolerance, 
and of ucOC with enhanced β-cell function, whereas cOC 
was associated with improved insulin sensitivity [35, 
51]. Cross-sectional studies reported that OC and ucOC 
were found negatively and positively associated with 
HOMA-IR in elderly men at high cardiovascular risk, 
respectively [36] and that ucOC was negatively correlated 
with markers of insulin resistance, central obesity, and 
the presence of MetS in postmenopausal women [54]. In 
a cross-sectional study, OC and ucOC were significantly 
lower in patients with MetS, independent of body mass 
index, and ucOC was positively correlated with HDL-C, 
while OC was negatively correlated with serum triglyc-
erides [37]. Thus, future studies should also address the 
actual individual contribution of cOC and ucOC to CV 
and metabolic health and disease in humans, in order 
to validate ucOC as a marker correlated with positive CV 
and metabolic outcomes.
OC has been also proposed to play a role in the develop-
ment of non-alcoholic fatty liver disease (NAFLD), which 
is considered as the hepatic feature of the metabolic syn-
drome and related insulin resistance. In a cross-sectional 
study, lower OC levels were negatively associated with 
serum alanine transaminase and aspartate transaminase 
levels [55] and lower serum OC levels were reported in a 
large Chinese cohort of patients with NAFLD, compared to 
non-NAFLD subjects [56]. Another end-stage complication 
of the metabolic syndrome is chronic kidney disease, asso-
ciated to deranged mineral, lipid and glucose metabolism 
and increased CV risk. In these patients, kidney, bone and 
metabolic alterations are interconnected with CV risk and 
disease, OC appears to have an altered metabolism and, 
together with other factors, may interfere with insulin 
concentrations and sensitivity [57].
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Open issues and future 
perspectives
Ample evidence supports a role for serum and locally-
produced OC in the pathophysiology of CV lesions and 
CV risk, also in combination with metabolic changes, 
including T2DM. To sum up, in some studies lower 
OC levels appear associated with greater CV risk, CV 
lesions and CV disease in an independent manner, 
although other reports do not support these findings. 
A partial explanation for such inconsistencies in the 
literature about OC and CV and metabolic diseases is 
given by the observation that serum OC levels are influ-
enced by ethnicity, gender and menopausal status [58], 
and that in some studies a non-linear, but U shaped, 
association curve between OC and CV/metabolic end-
points was found. Moreover, vitamin D status/supple-
mentation and the use of anti-vitamin K anticoagulant, 
which may per se affect circulating OC levels, are gen-
erally not taken into consideration in the available and 
cited clinical studies, indicating the need to include 
such parameters in future studies. These inconsisten-
cies suggest caution relative to the potential usefulness 
of measuring OC as a biomarker of CV risk and indicate 
the need to establish specific gender and ethnic refer-
ence values.
Moreover, the circulating OC assay methods varied 
among the different reports, suggesting caution, in some 
cases, in the comparison of the results obtained.
In any case, on the basis of the reported information, 
it is possible to speculate that a positive modulation of 
serum OC concentrations might be of value in the preven-
tion and treatment of vascular disease, although some 
open issues in this field are still present, as indicated 
below, and should be addressed by future studies.
1. The potential mechanisms underlying the association 
between serum OC and CV risk and disease remain 
unclear. On the one hand, since OC has been shown 
to promote pancreatic β-cell proliferation and insulin 
secretion and adiponectin release, thereby facilitat-
ing insulin sensitivity, lower OC levels may be associ-
ated to greater insulin resistance or T2DM and lower 
adiponectin, thus indirectly favoring CV damage. On 
the other hand, since the association of reduced OC 
with CV impairment is still present after adjustment 
for metabolic factors, lower OC may also directly and 
independently affect CV risk.
2. As above indicated, serum OC levels are influenced by 
a number of factors (ethnicity, gender, menopausal 
status, current drug treatment and vitamin D status, 
etc.) [58]. Specific reference values for total OC, cOC 
and ucOC need thus to be established, before propos-
ing the evaluation of circulating OC for CV and meta-
bolic risk assessment and follow-up.
3. In particular, interaction between OC and intermedi-
ary metabolism requires further studies, also evalu-
ating whether drugs able to modulate OC expression 
and secretion may be of use or should be avoided in 
subjects at risk for T2DM or already with this disease. 
Well-known examples of drugs impairing glucose 
metabolism as well as OC expression/serum concen-
trations are glucocorticoids and thiazide diuretics. 
On the contrary, dipeptidyl peptidase-IV inhibitors, 
widely used to treat T2DM, increase the half-life of OC 
and, thereby, its serum levels, suggesting the possi-
bility of a positive interaction between this hormone 
and glucagon-like peptide-1 to promote β-cell prolif-
eration and insulin secretion [10]. Such a relationship 
appears, however, very complex, as, at least in vitro, 
the glucagon-like peptide-1 analog liraglutide has 
been shown to attenuate osteoblastic differentiation 
of vascular smooth muscle cells, reducing locally-
produced OC and potentially counteracting arterial 
calcification [59].
In addition, if a causal relationship between lower circu-
lating OC and atherosclerosis progression will be estab-
lished, the above-reported observations may also suggest 
a potential role for OC as a novel therapeutical target for 
CV disease treatment.
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